Synapse - Noura Choudhury

Results (40)

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3–targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer

Review

Sands, J. M.; Champiat, S.; Hummel, H. D.; Paulson, K. G.; Borghaei, H.; Alvarez, J. B.; Carbone, D. P.; Carlisle, J. W.; Choudhury, N. J.; Clarke, J. M.; more...
Cancer (2025)

Fulltext@MSK | Save

Chromothripsis-mediated small cell lung carcinoma

Journal Article

Rekhtman, N.; Tischfield, S. E.; Febres-Aldana, C. A.; Lee, J. J. K.; Chang, J. C.; Herzberg, B. O.; Selenica, P.; Woo, H. J.; Vanderbilt, C. M.; Yang, S. R.; more...
Cancer Discovery (2025)

Fulltext@MSK | Save

Prevalence and prognostic impact of SEZ6 expression in a real-world cohort of patients with small-cell lung cancer

Meeting Abstract

Wang, S.; Luo, A.; Choudhury, N.; Wang, L.; Xu, D.; Jiang, F.; Roberts-Rapp, L.; Choi, Y. C.; Cai, M.; Rudra-Ganguly, N.; more...
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

A phase I first-in-human study of ABBV-011, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in patients with small cell lung cancer

Journal Article

Morgensztern, D.; Ready, N.; Johnson, M. L.; Dowlati, A.; Choudhury, N.; Carbone, D. P.; Schaefer, E.; Arnold, S. M.; Puri, S.; Piotrowska, Z.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Impact of brain metastases on safety and efficacy of MK-6070, a DLL3-targeting T cell engager, in small cell lung cancer

Meeting Abstract

Choudhury, N. J.; Beltran, H.; Johnson, M. L.; Schenk, E. L.; Sanborn, R. E.; Thompson, J. R.; Mamdani, H.; Dowlati, A.; Aggarwal, R. R.; Gramza, A. W.; more...
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN)

Meeting Abstract

Beltran, H.; Dowlati, A.; Jain, P.; Johnson, M. L.; Sanborn, R. E.; Thompson, J. R.; Mamdani, H.; Schenk, E. L.; Aggarwal, R. R.; Sankar, K.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer

Journal Article

Choudhury, N. J.; Lai, W. V.; Makhnin, A.; Heller, G.; Eng, J.; Li, B.; Preeshagul, I.; Santini, F. C.; Offin, M.; Ng, K.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors

Meeting Abstract

Chandana, S. R.; Choudhury, N. J.; Dowlati, A.; Chiang, A. C.; Garmezy, B.; Kim, J. H.; Byers, L. A.; Ahn, M. J.; Kim, T. M.; Kim, Y. C.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)